Santa Fe, New Mexico (PRWEB) October 15, 2013

October 15, 2013, Santa Fe, New Mexico

The Estrogen Gene Test Co. and General Genetics Corporation are pleased to announce the launch of a saliva-based test that can identify polymorphisms in all of the key estrogen metabolism genes.

Decades of research from top universities and institutions around the world reveal in studies that while mutations on single estrogen metabolism genes do not seem to raise the risk of breast cancer; women who possess two or more mutations are at greater risk have from a 2.7 to 13 fold increased risk of breast cancer than women without mutations.

80% of all breast cancer diagnosis is to women with no family history. EstroGeneTM allows physicians to pinpoint patients at greater risk and clinically intervene to improve estrogen metabolism function. In turn, this may lower their breast cancer risk regardless of their previous or current estrogen exposure, breast cancer status or fertility stage.

EstroGeneTM is recommended for all women and girls, however critical populations to test include women with past, present or future exposure to estrogen-based medications such as hormone replacement therapy, bio-identical hormones and in-vitro fertilization. Women treated for estrogen positive breast cancer, women with a family history of breast cancer and women with severe peri-menopausal symptoms should also test.

Since the first results of the landmark Womens Health Initiative study published in 2002, which highlighted the two-and-a-half times increased risk of breast cancer to women taking Hormone Replacement Therapy, physicians have struggled with the complexity of relieving menopausal or peri-menopausal symptoms and improving fertility. On the one hand, estrogen based medications may help relieve severe symptoms or promote fertility or allow egg retrieval. On the other hand, breast cancer, as well as other risks, are well known. Physicians no longer need to operate within the 2.5 times increased risk bell curve but can assess each patients risk individually and actively work to mitigate that risk by improving estrogen metabolism function.

Dr. Joseph Veltmann, Ph.D., Chief Scientific Officer for the Estrogen Gene Test Company, Founder of the Institute for Individualized Medicine and one of the worlds leading Nutrigenomic experts has been following 350 high risk women with mutation on the genes in the EstroGeneTM for the past 10 years. Out of the 350 women followed, none have developed the breast cancer disease or had a recurrence by following gene specific protocols to improve estrogen metabolism function. Dr. Veltmann commented, Since the vast majority of women have no family history of breast cancer, the increased availability of this test can allow women to take more meaningful control over their health. It may remove some of the mystery behind a breast cancer diagnosis and its prevention.

The Estrogen Gene Test Company has partnered with Clinical Testing Laboratory, a division of General Genetics Corporation, as its laboratory partner in the processing of Estrogene. Clinical Testing Laboratories is CLIA-certified and performs a wide variety of genetic analysis, including pharmacogenomics, genotyping and other sequencing services for partners around the world.

About Estrogen Gene Test Company The Estrogen Gene Test Co., http://www.estrogengenetest.com, is an outgrowth of the efforts of the Hormonal Cancer Foundation, http://www.hormonalcancer.org, to promote estrogen metabolism genetic testing before, during and after the use of estrogen medications or for women with estrogen receptor positive breast cancer. EGT is strongly committed to genetic testing to prevent breast cancer and is asking all women taking the test to participate in a Hormonal Cancer Foundation longitudinal study examining the outcome of changing gene expression to prevent breast cancer.

Original post:
The Estrogen Gene Test Co. and General Genetics Corporation Announce the Launch of EstroGeneTM, for Breast Cancer ...

Comments are closed.